ClinicalTrials.gg
CompletedNCT04061603Updated Aug 6, 2026Results posted

iCLAS™ for Persistent Atrial Fibrillation

An interventional study of Adagio AF Cryoablation System (iCLAS™) in Persistent Atrial Fibrillation, sponsored by Adagio Medical. Completed at 21 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Adagio Medical · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
215
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 993 studies in Atrial Fibrillation with a site in United States — 160 open to participants now, 220 under way, 15 of them phase 3. Atrial Fibrillation · United States.

Enrollment
249th of 679
215 · median 127
Started
2019
with 57 others
No phase
405 of 993
67 open now
Registered
605th of 993
by date

Among the 993 studies in Atrial Fibrillation with a site in United States, this one is the 249th largest by enrollment of the 679 interventional ones that give a count, is one of 58 that started in 2019, is one of 405 with no phase, and was the 605th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

160 of the 993 studies in Atrial Fibrillation with a site in United States are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 993 studies in Atrial Fibrillation with a site in United States, or all of them as a file.
02

Study summary

Clinical study to evaluate the safety and efficacy of the Adagio AF Cryoablation System (iCLAS™) in the ablation treatment of symptomatic, persistent atrial fibrillation (PsAF). Data will be used to support a pre-market application (PMA)

Read the detailed description

A staged pre-market, single-arm, clinical study designed to collect acute and long-term safety and efficacy data for the Adagio AF Cryoablation System (iCLAS™). Patient population will consist of symptomatic, persistent AF subjects completing a de novo ablation procedure. Enrollment will be 200 subjects at up to 20 global investigational sites. Subjects will receive an ablation with the ultra-low cryoablation device. Follow-up will include assessment at one, three, six, and twelve months.

03

Conditions studied

  • Persistent Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

IC1 Male or female between the ages of 18 and 80 years

IC2 Currently scheduled for an ablation of symptomatic, PsAF defined as continuous AF that is sustained > 7-days and ≤ 12 months and documented by the following: a. Physician's note indicating continuous AF > 7 days and ≤ 12 months, AND b. One of the following: i. 24-hour Holter within 180 days of enrollment showing continuous AF, OR ii. Two from any forms of rhythm monitoring (e.g., 12-lead ECGs or single lead ECGs) completed ≥ 7 days apart within 180 days of enrollment.

IC3 to at least one class I or III AAD. (Refractory defined as not effective, not tolerated or not desired)

IC4 Willingness, ability and commitment to participate in baseline and follow-up evaluations for the full length of the study

IC5 Willingness and ability to give an

Exclusion criteria

EXCLUSION CRITERIA

EC 1 In the opinion of the Investigator, any known to an atrial ablation, TEE, or anticoagulation. Including, but not limited to, the identification of any atrial thrombus or evidence of sepsis

EC 2 Any duration of continuous AF lasting longer than 12-months

EC 3 History of previous left atrial ablation or surgical treatment for AF/AFL/AT

EC 4 Atrial fibrillation secondary to electrolyte imbalance, active thyroid disease, or any other reversible or non-cardiac cause

EC 5 Structural heart disease as described below:

  1. (LVEF) \< 40% based on most recent TTE
  2. Left atrial size > 55 mm (parasternal long axis view) documented within 6-months of screening
  3. Class III or IV heart failure documented within the previous 12-months
  4. An implanted pacemaker or ICD
  5. Previous cardiac surgery, ventriculotomy, or atriotomy (excluding atriotomy for CABG),
  6. Previous cardiac valvular surgical or percutaneous procedure, or prosthetic valve
  7. Interatrial baffle, closure device, patch, or PFO occluder
  8. Presence of a left atrial appendage occlusion device
  9. Presence of any pulmonary vein stenting devices
  10. Coronary artery bypass graft (CABG) or PTCA procedure within 6 months prior to procedure
  11. Unstable angina or ongoing myocardial ischemia
  12. Myocardial infarction within the previous six (6) months prior to procedure
  13. Moderate or severe mitral insufficiency or stenosis based on most recent TTE
  14. Atrial myxoma
  15. Significant congential anomaly

EC 6 > 40

  • BMI >35 and no prior sponsor approval into the study

EC 7 Any previous history of cryoglobulinemia

EC 8 History of blood clotting or bleeding disease

EC 9 History of severe requiring use in the previous 12-months

EC 10 History of severe sleep apnea (AHI > 30) not currently treated with a CPAP machine or other mechanical device

EC 11 Any prior history of documented cerebral infarct including recent (within one year) or systemic embolism (excluding a post-operative DVT)

EC 12 Any prior history or current evidence of hemidiaphragmatic paralysis

EC 13 Pregnant or lactating (current or anticipated during study follow-up)

EC 14 Current enrollment in any other study protocol where testing or results from that study may interfere with the procedure or outcome measurements for this study

EC 15 Any other condition that, in the judgment of the investigator, makes the patient a poor candidate for this procedure, the study or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, terminal illness with a of less than two years, extensive travel away from the research center, COVID-19 related concerns)

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
215 participants (actual)

Study arms

  • Experimental
    iCLAS Ablation

    Ablation of the left and right atrium with the Adagio Medical iCLAS System

    Device: Adagio AF Cryoablation System (iCLAS™)

Interventions

  • DeviceAdagio AF Cryoablation System (iCLAS™)

    Endovascular ablation of the left and right atrium

06

What researchers measure

Primary outcomes

  1. Analysis of the Proportion of Subjects Who Are Free From Device/Procedure Related Major Adverse Events (MAEs) That Occur Following the Cryoablation Procedure

    Analysis of the proportion of subjects who are free from device/procedure related Major Adverse Events (MAEs) that occur following the cryoablation procedure. MAEs include any of the following: * Death * Myocardial infarction * Cardiac perforation/pericardial tamponade * Cerebral infarct or systemic embolism * Major bleeding requiring transfusion of blood products * Mitral or tricuspid valve damage * Symptomatic pulmonary vein stenosis * Severe (≥ 70%) pulmonary vein stenosis * Permanent phrenic nerve injury * Access site complications requiring pharmacological or surgical intervention * Atrio-esophageal fistula * Pericarditis * Heart block requiring a permanent pacemaker * Vagal nerve injury with GI dysmotility * Other serious adverse device effects (SADEs), including TIAs, adjudicated by an independent Clinical Events Committee (CEC) as "probably or definitely related" to the Adagio System

    Time frame: 12-months

  2. Analysis of the Proportion of Subjects Receiving a Single Cryoablation Who Are Free From Any Documented Left Atrial Arrhythmia (AF/AFL/AT) Following the Blanking Period Lasting Longer Than 30 Seconds on a Continuous 24-hour ECG Recording (Holter Monitor).

    Analysis of the proportion of subjects receiving a single cryoablation who are free from any documented left atrial arrhythmia (AF/AFL/AT) following the Blanking Period lasting longer than 30 seconds on a continuous 24-hour ECG recording (Holter monitor). The primary effectiveness endpoint will be based on a centralized core lab interpretation of the recordings used in the endpoint analysis.

    Time frame: 12-months

Secondary outcomes

  1. Analysis of the Proportion of Subjects With Acute Procedural (Ablation) Success

    Percentage of patients with documentation of pulmonary vein isolation (LSPV, LIPV, RSPV, RIPV) and posterior wall isolation (PWI) and cavo-tricuspid isthmus (CTI) bidirectional block (BDB) following the last ablation of PV, PW, and CTI.

    Time frame: 20-minutes following last ablation

07

Results

Posted Aug 6, 2026

Participant flow

215 patients were enrolled

Participant flow — Overall Study
MilestoneiCLAS Ablation
Started189
Completed175
Not completed14

Outcome measures

PrimaryAnalysis of the Proportion of Subjects Who Are Free From Device/Procedure Related Major Adverse Events (MAEs) That Occur Following the Cryoablation Procedure

Analysis of the proportion of subjects who are free from device/procedure related Major Adverse Events (MAEs) that occur following the cryoablation procedure. MAEs include any of the following: * Death * Myocardial infarction * Cardiac perforation/pericardial tamponade * Cerebral infarct or systemic embolism * Major bleeding requiring transfusion of blood products * Mitral or tricuspid valve damage * Symptomatic pulmonary vein stenosis * Severe (≥ 70%) pulmonary vein stenosis * Permanent phrenic nerve injury * Access site complications requiring pharmacological or surgical intervention * Atrio-esophageal fistula * Pericarditis * Heart block requiring a permanent pacemaker * Vagal nerve injury with GI dysmotility * Other serious adverse device effects (SADEs), including TIAs, adjudicated by an independent Clinical Events Committee (CEC) as "probably or definitely related" to the Adagio System

Time frame:
12-months
Reported as:
Count of participants · Participants
Analysis of the Proportion of Subjects Who Are Free From Device/Procedure Related Major Adverse Events (MAEs) That Occur Following the Cryoablation Procedure
ParticipantsSafety Cohort
Analysis of the Proportion of Subjects Who Are Free From Device/Procedure Related Major Adverse Events (MAEs) That Occur Following the Cryoablation Procedure3
PrimaryAnalysis of the Proportion of Subjects Receiving a Single Cryoablation Who Are Free From Any Documented Left Atrial Arrhythmia (AF/AFL/AT) Following the Blanking Period Lasting Longer Than 30 Seconds on a Continuous 24-hour ECG Recording (Holter Monitor).

Analysis of the proportion of subjects receiving a single cryoablation who are free from any documented left atrial arrhythmia (AF/AFL/AT) following the Blanking Period lasting longer than 30 seconds on a continuous 24-hour ECG recording (Holter monitor). The primary effectiveness endpoint will be based on a centralized core lab interpretation of the recordings used in the endpoint analysis.

Time frame:
12-months
Reported as:
Count of participants · Participants
Analysis of the Proportion of Subjects Receiving a Single Cryoablation Who Are Free From Any Documented Left Atrial Arrhythmia (AF/AFL/AT) Following the Blanking Period Lasting Longer Than 30 Seconds on a Continuous 24-hour ECG Recording (Holter Monitor).
ParticipantsModified Intention-to-treat (mITT) Population
Analysis of the Proportion of Subjects Receiving a Single Cryoablation Who Are Free From Any Documented Left Atrial Arrhythmia (AF/AFL/AT) Following the Blanking Period Lasting Longer Than 30 Seconds on a Continuous 24-hour ECG Recording (Holter Monitor).97
SecondaryAnalysis of the Proportion of Subjects With Acute Procedural (Ablation) Success

Percentage of patients with documentation of pulmonary vein isolation (LSPV, LIPV, RSPV, RIPV) and posterior wall isolation (PWI) and cavo-tricuspid isthmus (CTI) bidirectional block (BDB) following the last ablation of PV, PW, and CTI.

Time frame:
20-minutes following last ablation
Reported as:
Number · percentage of participants
Analysis of the Proportion of Subjects With Acute Procedural (Ablation) Success
percentage of participantsModified Intention-to-treat (mITT) Population
PVI- LSPV Achieved94.2
PVI- LIPV Achieved94.9
PVI- RSPV Achieved97.8
PVI- RIPV Achieved97.1
PWI96.4
CTI BDB Achieved87.2

Adverse events

Collected over 12-month. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
iCLAS Ablation3/189 (1.6%)10/189 (5.3%)14/189 (7.4%)
Most frequent serious events
Most frequent serious events
EventiCLAS Ablation
Vascular access site complicationsVascular disorders3/189
Phrenic nerve injuryInjury, poisoning and procedural complications2/189
Esophageal injuryGastrointestinal disorders2/189
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders1/189
Cerebral infarct or systemic embolismNervous system disorders1/189
Vascular access site bleedingInjury, poisoning and procedural complications1/189
Most frequent other events
Most frequent other events
EventiCLAS Ablation
Vascular access site complicationsVascular disorders7/189
Phrenic nerve injuryInjury, poisoning and procedural complications7/189

Baseline characteristics

Age, Continuous
Age, Continuous(years)iCLAS Ablation
Mean65.5 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)iCLAS Ablation
Female50
Male139
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)iCLAS Ablation
Left Ventricular Ejection Fraction (LVEF)
Left Ventricular Ejection Fraction (LVEF)(%)iCLAS Ablation
Mean56 ± 7.4
08

Study locations

21 sites
  • Grandview Medical Center
    Birmingham, Alabama 35243, United States
  • Banner Health
    Phoenix, Arizona 85006, United States
  • St. Bernards Medical Center
    Jonesboro, Arkansas 72401, United States
  • University of California San Diego
    San Diego, California 92093, United States
  • South Denver Cardiology Associates
    Denver, Colorado 80120, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • Emory St. Joseph's Hospital
    Atlanta, Georgia 30342, United States
  • Northwestern University
    Evanston, Illinois 60208, United States
  • Prairie Heart Research Institute
    Springfield, Illinois 62701, United States
  • Johns Hopkins University
    Baltimore, Maryland 21205, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • The Valley Hospital
    Ridgewood, New Jersey 07450, United States
  • New Mexico Heart Institute
    Albuquerque, New Mexico 87102, United States
  • Staten Island University Hospital - Northwell Health
    Staten Island, New York 10305, United States
  • Ohio Health Research Institute
    Columbus, Ohio 43214, United States
  • Baylor St. Luke's Medical Center
    Houston, Texas 77030, United States
  • Onze Lieve Vrouwziekenhuis
    Aalst, Belgium
  • ZNA Middelheim
    Antwerp, Belgium
  • Southlake Regional Medical Centre
    Newmarket, Ontario L3Y 2P9, Canada
  • St. Antonius Ziekenhuis Nieuwegein
    Nieuwegein, Netherlands
  • Erasmus University Medical Center
    Rotterdam, 3015 GD, Netherlands
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Aug 2023, 44 months.

Results were first posted in Aug 2026, 2 years 11 months after primary completion.

Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 44 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2019
First posted
Aug 20, 2019
StartActual
Dec 9, 2019
Primary completionActual
Aug 30, 2023
CompletionActual
Aug 30, 2024
Results first posted
Aug 6, 2026
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04061603
Lead sponsor
Adagio Medical
Responsible party
Sponsor
First posted
Aug 20, 2019
Start date
Dec 9, 2019
Primary completion
Aug 30, 2023
Completion
Aug 30, 2024
Results posted
Aug 6, 2026
Last update
Aug 6, 2026

Study contacts

Suneet Mittal, MD
principal investigator · Valley Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion